ArticleInfection and immunity2011
Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.
Article in Infection and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Evaluation of immune responses toFrontiers in veterinary science · 2022Pooled it
- Meta-Analysis and Advancement of Brucellosis Vaccinology.PloS one · 2016Pooled it
- Zinc Homeostasis inBiology · 2026Article
- Pre-treatment IFN-γ levels are associated with chronic progression in patients with brucellosis: a retrospective study.Frontiers in immunology · 2026Article
- Brucellosis: Bacteriology, pathogenesis, epidemiology and role of the metallophores in virulence: a review.Frontiers in cellular and infection microbiology · 2025Review
- Review
- Genome-wide analysis of Brucella melitensis growth in spleen of infected mice allows rational selection of new vaccine candidates.PLoS pathogens · 2024Article
- Parenteral Vaccination with a LiveMicroorganisms · 2024Article
- Interactions between B cells and T follicular regulatory cells enhance susceptibility to Brucella infection independent of the anti-Brucella humoral response.PLoS pathogens · 2023Article
- Scanning iron response regulator binding sites using Dap-seq in the Brucella genome.PLoS neglected tropical diseases · 2023Article
- A Single Nasal Dose Vaccination with a Brucella abortus Mutant Potently Protects against Pulmonary Infection.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice.Vaccines · 2023Article
- Protection against virulentClinical and experimental vaccine research · 2022Article
- Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis.Frontiers in microbiology · 2022Review
- Live mucosal vaccination stimulates potent protectionFrontiers in immunology · 2022Article
- Evaluation of Brucellosis Vaccines: A Comprehensive Review.Frontiers in veterinary science · 2022Review
- Evaluation of the immunogenicity and efficacy of a chimeric OMP25-OMP31 antigen in BALB/c mice.Veterinary medicine and science · 2021Article
- Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology.Veterinary research · 2021Article
- B Cells Inhibit CD4Infection and immunity · 2020Article
- Live vaccine consisting of attenuated Salmonella secreting and delivering Brucella ribosomal protein L7/L12 induces humoral and cellular immune responses and protects mice against virulent Brucella abortus 544 challenge.Veterinary research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Zoonotic transmission of brucellosis often results from exposure to Brucella-infected livestock, feral animals, or wildlife or frequently via consumption of unpasteurized milk products or raw meat. Since natural infection of humans often occurs by the oral route, mucosal vaccination may offer a means to confer protection for both mucosal and systemic tissues. Significant efforts have focused on developing a live brucellosis vaccine, and deletion of the znuA gene involved in zinc transport has been found to attenuate Brucella abortus. A similar mutation has been adapted for Brucella melitensis and tested to determine whether oral administration of ΔznuA B. melitensis can confer protection against nasal B. melitensis challenge. A single oral vaccination with ΔznuA B. melitensis rapidly cleared from mice within 2 weeks and effectively protected mice upon nasal challenge with wild-type B. melitensis 16M. In 83% of the vaccinated mice, no detectable brucellae were found in their spleens, unlike with phosphate-buffered saline (PBS)-dosed mice, and vaccination also enhanced the clearance of brucellae from the lungs. Moreover, vaccinated gamma interferon-deficient (IFN-γ(-/-)) mice also showed protection in both spleens and lungs, albeit protection that was not as effective as in immunocompetent mice. Although IFN-γ, interleukin 17 (IL-17), and IL-22 were stimulated by these live vaccines, only RB51-mediated protection was codependent upon IL-17 in BALB/c mice. These data suggest that oral immunization with the live, attenuated ΔznuA B. melitensis vaccine provides an attractive strategy to protect against inhalational infection with virulent B. melitensis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.